Gulick RM, Mellors JW, Havlir D.
et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med.2000;133:35-39.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Hammer SM, Katzenstein DA, Hughes MD.
et al. A trial comparing nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med.1996;335:1081-1090.
Ledergerber B, Egger M, Erard V.
et al. AIDS-related opportunistic illnesses occurring after initiation of
potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA.1999;282:2220-2226.
Hogg RS, Heath KV, Yip B.
et al. Improved survival among HIV-infected individuals following initiation
of antiretroviral therapy. JAMA.1998;279:450-454.
Detels R, Munoz A, McFarlane G.
et al. for the Multicenter AIDS Cohort Study Investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and
death in men with known HIV infection duration. JAMA.1998;280:1497-1503.
Palella Jr FJ, Delaney KM, Moorman AC.
et al. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Autran B, Carcelain G, Li TS.
et al. Positive effects of combined antiretroviral therapy on CD4+
t-cell homeostasis and function in advanced HIV disease. Science.1997;277:112-116.
Kalish LA, McIntosh K, Read JS.
et al. Evaluation of human immunodeficiency virus (HIV) type 1 load, CD4 T
cell level, and clinical class as time-fixed and time-varying markers of disease
progression in HIV-1-infected children. J Infect Dis.1999;180:1514-1520.
Mellors JW, Munoz A, Giorgi JV.
et al. Plasma viral load and CD4+ lymphocytes as prognostic markers
of HIV-1 infection. Ann Intern Med.1997;126:946-954.
Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in
Davey RT, Murphy RL, Graziano FM.
et al. Immunologic and virologic effects of subcutaneous interleukin 2 in
combination with antiretroviral therapy: a randomized controlled trial. JAMA.2000;284:183-189.
Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature.1987;327:473-476.
Lutz H, Hofmann-Lehmann R, Leutenegger C.
et al. Vaccination of cats with recombinant envelope glycoprotein of feline
immunodeficiency virus: decreased viral load after challenge infection. AIDS Res Hum Retroviruses.1996;12:431-433.
Mossman SP, Bex F, Berglund P.
et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14
disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120
subunit vaccine. J Virol.1996;70:1953-1960.
Siebelink KH, Tijhaar E, Huisman RC.
et al. Enhancement of feline immunodeficiency virus infection after immunization
with envelope glycoprotein subunit vaccines. J Virol.1995;69:3704-3711.
Richardson J, Moraillon A, Baud S, Cuisinier AM, Sonigo P, Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after
DNA vaccination with the FIV envelope. J Virol.1997;71:9640-9649.
Goebel FD, Mannhalter JW, Belshe RB.
et al. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results
of a large randomized, controlled trial. AIDS.1999;13:1461-1468.
Eron JJ, Ashby MA, Giordano MF.
et al. Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet.1996;348:1547-1551.
Birx DL, Loomis-Price LD, Aronson N.
et al. Efficacy testing of recombinant human immunodeficiency virus (HIV)
gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. J Infect Dis.2000;181:881-889.
Turner JL, Trauger RJ, Daigle AE, Carlo DJ. HIV-1 immunogen induction of HIV-1 specific delayed-type hypersensitivity:
results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS.1994;8:1429-1435.
Trauger RJ, Ferre F, Daigle AE.
et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency
virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage
of CD4 cells. J Infect Dis.1994;169:1256-1264.
Levine AM, Groshen S, Allen J.
et al. Initial studies on active immunization of HIV-1 infected subjects using
a gp120-depleted HIV-1 immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol.1996;11:351-364.
Moss RB, Ferre F, Levine A.
et al. Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects
receiving the HIV-1 immunogen and antiviral drug therapy. J Clin Immunol.1996;16:266-271.
Moss RB, Wallace MR, Giermakowska WK.
et al. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated
immune responses after treatment with an HIV-1 immunogen. J Infect Dis.1999;180:641-648.
Choi DJ, Dube S, Spicer TP, Slade HB, Jensen FC, Poiesz BJ. HIV type 1 isolate Z321, the strain used to make a therapeutic HIV
type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses.1997;13:357-361.
Dawson JD, Lagakos SW. Size and power of two-sample tests of repeated measures. Biometrics.1993;49:1022-1032.
Bradley JV. Distribution-Free Statistical Tests. Englewood Cliffs, NJ: Prentice-Hall; 1968.
Lan KKG, DeMets DL. Changing frequency of interim analysis in sequential monitoring. Biometrics.1989;45:1017-1020.
Chalmers I. Underreporting research is scientific misconduct. JAMA.1990;263:1405-1408.
Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science: evidence from
a national survey of faculty. JAMA.1997;277:1224-1228.